APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., will launch its new APP Drug Hotline on Wednesday, November 10, 2010.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., launched its new APP Drug Hotline on Wednesday, November 10, 2010. The APP Drug Hotline has been established to assist healthcare professionals dealing with critical drug shortage issues.
An experienced customer service team will respond to inquires from healthcare professionals seeking information on whether APP’s product portfolio can augment the supply of specific drugs currently on the shortage lists of the FDA and American Society of Health-System Pharmacists (ASHP), a company press release stated. Hotline staff will provide callers with real-time information about APP’s available supply of specific drugs currently on drug shortage and about upcoming APP product releases, as well as help callers track their APP orders.
“Throughout the years, APP Pharmaceuticals has demonstrated that it can meet the challenges of critical drug shortages, and we are acutely aware of the pressure that healthcare professionals are under when a needed drug is unavailable. We have worked collaboratively with the FDA to alleviate shortages for many products ranging from acyclovir to heparin and most recently propofol,” said John Ducker, president and CEO, APP Pharmaceuticals. “Responsiveness is APP’s commitment to healthcare professionals and we understand the importance of product supply meeting patient demand.”
Healthcare professionals can reach the APP Drug Hotline by calling 888-386-1300, option 6, Monday through Friday, 7 a.m. to 6 p.m. (CST).
Information on current inventory and product availability can also be found at the company’s website, www.APPpharma.com, under the heading Product Availability Information.